Photo courtesy of “Systems of Care Yakima”.
Lundbeck and Forest Labs. This picture is an old advert for Cipramil. Who’s the ass?
Citalopram and Escitalopram: Sudden death, Kickback, Bribes and falsification of the effectiveness of Celexa. Two more articles were published this week involving the dubious Lundbeck and their American partners Forest Labs.
The Irish medical Times reported this week that Citalopram and escitalopram have been found to cause a dose-dependent prolongation of the QT interval. Link. This can cause serious heart problems which can be fatal Link.
Last October the Irish Medicines Board, IMB, issued a warning that Citalopram could cause this problem. The warning also made a week referrence to Escitalopram. I pointed out that considering a Brussles Court found both products to be the same, surely the same warning should be attached to both, albeit identical, medications. Link. Why has it taken so long to admit that the problem can be caused by both products?
Another interesting point in the same Article is that Healthcare professionals are advised to review elderly patients dosage and if needed gradually reduce the dose accordingly. The Article further states that “the product information advises on how to minimise the risk of withdrawal symptoms”. WITHDRAWAL SYMPTOMS? Is Lundbeck finally admitting that this medication can be highly addictive? Pharmaceutical companies rarely use the words “withdrawal symptoms” and normally prefer to use the word “discontinuation” as they never admit that SSRI’s are addictive.
Another Suit involving kickbacks and bribes by Forest Labs.
A whistleblower suit unsealed in Maryland federal court on Friday claims a Forest Laboratories Inc. unit paid kickbacks to the main author of a federally funded antidepressant drug study so he would rig it in favor of the company’s drug Celexa, in violation of the False Claims Act.
The suit, originally filed by relator and psychologist H. Edmund Pigott in March, alleges that Forest paid kickbacks and bribes to Dr. John Rush of the University of Texas’ Southwest Medical Center, the principal investigator of the $35 million study, contracted by the National Institute of Mental Health in 1999, as well as other investigators.
The suit claims that Rush and his fellow investigators chose Celexa as the only antidepressant employed in the first leg of the study, giving it a huge advantage over competing antidepressants, which caused falsification and overstatement of the effectiveness of Celexa when the study’s findings were published in 2006. Full Article here